Andrew has extensive board and business experience both in Biotech and major Pharmaceutical companies. Currently Chairman of Blueberry Therapeutics, Chairman NeRRe Therapeutics, Senior Advisor to HealthCap VC, and a Consultant & Advisor to Boards and Executive teams, Director of Amulet Consulting specialising in Board and Senior Executive advisory roles with Biotech and Healthcare companies.
Previously Chairman of Wilson Therapeutics (successful exit $855m in 2018) and CEO of Algeta 2014 (a top 25 biotech focused on oncology with a market cap and exit USD 2.9 Billion) with R&D / manufacturing in Europe and co-promotion in the USA. Ten years main board experience and committee experience includes Audit Committee, Compensation Committee, Corporate Governance and Regulatory Risk Committee and Board sub groups for R&D, Manufacturing, Financing, Licensing and Clinical Development. International career spans CEO, country/ business management, marketing, sales, medical/regulatory, manufacturing.
Assignments include roles in the USA, UK, Italy, Switzerland and Scandinavia. Wide range of major licensing deals and product launch experience covering the major therapeutic areas and eight blockbuster launches.
Andrew gained a BPharm Hons from Nottingham University School of Pharmacy.